Year |
Citation |
Score |
2023 |
Abbaoui A, Fatoba O, Yamashita T. Meningeal T cells function in the central nervous system homeostasis and neurodegenerative diseases. Frontiers in Cellular Neuroscience. 17: 1181071. PMID 37608988 DOI: 10.3389/fncel.2023.1181071 |
0.456 |
|
2021 |
Fatoba O, Itokazu T, Yamashita T. Complement cascade functions during brain development and neurodegeneration. The Febs Journal. PMID 33599083 DOI: 10.1111/febs.15772 |
0.458 |
|
2020 |
Fatoba O, Itokazu T, Yamashita T. Microglia as therapeutic target in central nervous system disorders. Journal of Pharmacological Sciences. 144: 102-118. PMID 32921391 DOI: 10.1016/J.Jphs.2020.07.004 |
0.496 |
|
2020 |
Fatoba O, Ohtake Y, Itokazu T, Yamashita T. Immunotherapies in Huntington's disease and α-Synucleinopathies. Frontiers in Immunology. 11: 337. PMID 32161599 DOI: 10.3389/Fimmu.2020.00337 |
0.506 |
|
2019 |
Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Author Correction: Laquinimod treatment in the R6/2 mouse model. Scientific Reports. 9: 4960. PMID 30874566 DOI: 10.1038/S41598-018-37926-4 |
0.404 |
|
2018 |
Fatoba O, Kloster E, Reick C, Saft C, Gold R, Epplen JT, Arning L, Ellrichmann G. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease. Experimental Neurology. PMID 29309751 DOI: 10.1016/J.Expneurol.2018.01.001 |
0.549 |
|
2017 |
Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Laquinimod treatment in the R6/2 mouse model. Scientific Reports. 7: 4947. PMID 28694434 DOI: 10.1038/S41598-017-04990-1 |
0.514 |
|
2017 |
Pitarokoili K, Kohle F, Motte J, Fatoba O, Pedreiturria X, Gold R, Yoon MS. Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis. Journal of Neuroimmunology. 309: 58-67. PMID 28601289 DOI: 10.1016/J.Jneuroim.2017.05.008 |
0.558 |
|
2017 |
Vöpel T, Bravo-Rodriguez K, Mittal S, Vachharajani S, Gnutt D, Sharma A, Steinhof A, Fatoba O, Ellrichmann G, Nshanian M, Heid C, Loo JA, Klärner FG, Schrader T, Bitan G, et al. Inhibition of Huntingtin Exon-1 Aggregation by the Molecular Tweezer CLR01. Journal of the American Chemical Society. PMID 28406616 DOI: 10.1021/Jacs.6B11039 |
0.571 |
|
2016 |
Fatoba O, Kloster E, Saft C, Gold R, Arning L, Ellrichmann G. L22 Intranasal application of NPY and NPY13–36 ameliorate disease pathology in R6/2 mouse model of huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.277 |
0.508 |
|
2016 |
Ellrichmann G, Blusch A, Fatoba O, Brunner J, Pitarokoili K, Hayardeny L, Saft C, Gold R. L7 Laquinimod in the R6/2 mouse model of huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.262 |
0.6 |
|
2016 |
Fatoba O, Ellrichmann G, Saft C, Kloster E, Gold R, Arning L. Activation of neuropeptide-Y2 receptor mediates neuroprotection in cellular model of Huntington's disease Neuropeptides. 55: 5. DOI: 10.1016/J.Npep.2015.11.012 |
0.455 |
|
Show low-probability matches. |